BFM
NVCR icon

Boothbay Fund Management’s NovoCure NVCR Stock Holding History

Boothbay Fund Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,600
Closed -$2.14M – 2139
2023
Q1 		$2.14M Buy
+35,600
New +$2.84M 0.04% 627
2016
Q2 		– Sell
-21,800
Closed -$316K – 575
2016
Q1 		$316K Buy
+21,800
New +$313K 0.24% 134

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Boothbay Fund Management's NVCR Position: Q1 2026 in Review

Boothbay Fund Management increased its NovoCure (NVCR) stake by 63% in Q1 2026, buying an estimated $398K and bringing the position to 82,412 shares worth $898K. The position accounts for 0.01% of the portfolio, ranked #1004.

Boothbay Fund Management first reported a position in NVCR in Q1 2023 and has held it in 3 quarters since. The position peaked at $2.14M in Q1 2023. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Boothbay Fund Management held 82,412 shares of NovoCure worth $898K as of Q1 2026.
  • Boothbay Fund Management bought 31,870 NovoCure shares in Q1 2026, an estimated $398K.
  • NovoCure made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1004 holding.
  • Boothbay Fund Management first reported a position in NovoCure in Q1 2023 and has held it in 3 quarters since.
  • Boothbay Fund Management's NovoCure position peaked at $2.14M in Q1 2023.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.